Provectus Biopharmaceuticals (PVCT) 10-Q 10 Nov 21 2021 FY Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2021	Nov. 09, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	001-36457
Entity Registrant Name	PROVECTUS BIOPHARMACEUTICALS, INC.
Entity Central Index Key	0000315545
Entity Tax Identification Number	90-0031917
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	10025 Investment Drive
Entity Address, Address Line Two	Suite 250
Entity Address, City or Town	Knoxville
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37932
City Area Code	866
Local Phone Number	594-5999
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		419,447,119

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current Assets:
Cash and cash equivalents	$ 254,083	$ 97,231
Short-term receivables - legal fees, settlement and other, net	1,354	3,930
Prepaid expenses	251,111	322,518
Total Current Assets	506,548	423,679
Equipment and furnishings, less accumulated depreciation of $87,962 and $78,313, respectively	35,052	44,701
Operating lease right-of-use asset	58,736	120,821
Total Assets	600,336	589,201
Current Liabilities:
Accounts payable - trade	1,259,623	956,860
Deposit for purchase of Series D-1 Preferred Stock	150,000
Other accrued expenses	1,806,000	1,500,782
Current portion of accrued interest		2,774,968
Current portion of accrued interest - related parties	2,044	1,766,493
Current portion of note payable	68,392	236,228
Current portion of convertible notes payable		16,622,000
Current portion of convertible notes payable - related parties	200,000	6,770,000
Current portion of operating lease liability	62,920	84,383
Total Current Liabilities	3,548,979	30,711,714
Note payable, non-current portion		39,061
Operating lease liability, non-current portion		44,783
Total Liabilities	3,548,979	30,795,558
Commitments and contingencies (Note 10)
Stockholders’ Deficiency:
Common stock; par value $0.001 per share; 1,000,000,000 shares authorized; 419,447,119 and 398,807,037 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively	419,448	398,808
Additional paid-in capital	241,440,106	209,923,347
Accumulated other comprehensive loss	(34,574)	(34,097)
Accumulated deficit	(244,795,215)	(240,494,415)
Total Stockholders’ Deficiency	(2,948,643)	(30,206,357)
Total Liabilities and Stockholders’ Deficiency	600,336	589,201
Series B Convertible Preferred Stock [Member]
Stockholders’ Deficiency:
Preferred stock value
Series D Convertible Preferred Stock [Member]
Stockholders’ Deficiency:
Preferred stock value	12,373
Series D-1 Convertible Preferred Stock [Member]
Stockholders’ Deficiency:
Preferred stock value	$ 9,219

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Accumulated depreciation	$ 87,962	$ 78,313
Preferred Stock, Par Value	$ 0.001	$ 0.001
Preferred stock, shares authorized	25,000,000	25,000,000
Common Stock, Par or Stated Value Per Share		$ 0.001
Common Stock, Shares Authorized		1,000,000,000
Common Stock, Shares, Outstanding	419,447,119	398,807,037
Series B Convertible Preferred Stock [Member]
Preferred stock, shares authorized	240,000	240,000
Preferred Stock, Shares Issued	0	100
Preferred Stock, Shares Outstanding	0	100
Preferred Stock, Liquidation Preference Per Share	$ 0	$ 3,500
Series D Convertible Preferred Stock [Member]
Preferred stock, shares authorized	12,374,000	12,374,000
Preferred Stock, Shares Issued	12,373,247	0
Preferred Stock, Shares Outstanding	12,373,247	0
Preferred Stock, Liquidation Preference Per Share	$ 14,164,889	$ 0
Series D-1 Convertible Preferred Stock [Member]
Preferred stock, shares authorized	9,441,000	9,441,000
Preferred Stock, Shares Issued	9,218,449	0
Preferred Stock, Shares Outstanding	9,218,449	0
Preferred Stock, Liquidation Preference Per Share	$ 105,532,804	$ 0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Operating Expenses:
Research and development	$ 608,653	$ 667,523	$ 1,866,776	$ 2,273,423
General and administrative	438,578	434,355	1,583,148	1,487,543
Total Operating Expenses	1,047,231	1,101,878	3,449,924	3,760,966
Total Operating Loss	(1,047,231)	(1,101,878)	(3,449,924)	(3,760,966)
Other Income/(Expense):
EIDL grant				3,000
Research and development tax credit	(507)	1	31,637	27,187
Investment and interest income	1	823	2	3,414
Gain from extinguishment			63,094
Interest expense	(3,522)	(463,390)	(945,609)	(1,278,945)
Total Other Expense, Net	(4,028)	(462,566)	(850,876)	(1,245,344)
Net Loss	$ (1,051,259)	$ (1,564,444)	$ (4,300,800)	$ (5,006,310)
Basic and Diluted Loss Per Common Share	$ 0	$ 0	$ (0.01)	$ (0.01)
Weighted Average Number of Common Shares Outstanding - Basic and Diluted	409,961,614	393,495,431	405,286,784	393,443,141

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Net Loss	$ (1,051,259)	$ (1,564,444)	$ (4,300,800)	$ (5,006,310)
Other Comprehensive Loss:
Foreign currency translation adjustments	(193)	(1,652)	(477)	(8,446)
Total Comprehensive Loss	$ (1,051,452)	$ (1,566,096)	$ (4,301,277)	$ (5,014,756)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Deficiency (Unaudited) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020
Balance	$ (2,610,679)	$ (31,615,870)	$ (30,206,357)	$ (27,476,982)	$ (25,865,560)	$ (24,072,112)	$ (30,206,357)	$ (24,072,112)
Common stock issued for services		1,675		2,813	1,150
Common stock issued upon exercise of warrants	711,713	10,660	239,850	325,401		42,640
Common stock	1,775		19,750
Warrants issued for services		488		865
Conversion of PRH Notes to Series D Preferred Stock		3,541,222
Conversion of PRH Notes to Series D-1 Preferred Stock		27,031,858
Conversion of Series B Preferred Stock to Common Stock
Conversion of Series D-1 Preferred Stock to Common Stock
Net loss	(1,051,259)	(1,579,591)	(1,669,950)	(1,564,444)	(1,614,805)	(1,827,061)	(4,300,800)	(5,006,310)
Other comprehensive (loss) income	(193)	(1,121)	837	(1,652)	2,233	(9,027)	(477)	(8,446)
Balance	(2,948,643)	(2,610,679)	(31,615,870)	(28,713,999)	(27,476,982)	(25,865,560)	(2,948,643)	(28,713,999)
Common Stock [Member]
Balance	$ 403,783	$ 403,558	$ 398,808	$ 390,714	$ 390,689	$ 389,889	$ 398,808	$ 389,889
Beginning balance, shares	403,782,037	403,557,037	398,807,037	390,714,475	390,689,475	389,889,475	398,807,037	389,889,475
Common stock issued for services		$ 25		$ 38	$ 25
Common stock issued for services		25,000		37,500	25,000
Common stock issued upon exercise of warrants	$ 13,353	$ 200	$ 4,500	$ 6,105		$ 800
Common stock issued upon exercise of warrants	13,352,966	200,000	4,500,000	6,105,062		800,000
Common stock	$ 25		$ 250
Common stock, shares	25,000		250,000
Warrants issued for services
Conversion of PRH Notes to Series D Preferred Stock
Conversion of PRH Notes to Series D-1 Preferred Stock
Conversion of Series B Preferred Stock to Common Stock	$ 66
Conversion of Series B Preferred Stock to Common Stock, shares	65,666
Conversion of Series D-1 Preferred Stock to Common Stock	$ 2,221
Conversion of Series D-1 Preferred Stock to Common Stock	2,221,450
Net loss
Other comprehensive (loss) income
Balance	$ 419,448	$ 403,783	$ 403,558	$ 396,857	$ 390,714	$ 390,689	$ 419,448	$ 396,857
Ending balance, shares	419,447,119	403,782,037	403,557,037	396,857,037	390,714,475	390,689,475	419,447,119	396,857,037
Additional Paid-in Capital [Member]
Balance	$ 240,742,061	$ 210,178,197	$ 209,923,347	$ 209,421,800	$ 209,420,675	$ 209,378,835	$ 209,923,347	$ 209,378,835
Common stock issued for services		1,650		2,775	1,125
Common stock issued upon exercise of warrants	698,360	10,460	235,350	319,296		41,840
Common stock	1,750		19,500
Warrants issued for services		488		865
Conversion of PRH Notes to Series D Preferred Stock		3,528,849
Conversion of PRH Notes to Series D-1 Preferred Stock		27,022,417
Conversion of Series B Preferred Stock to Common Stock	(66)
Conversion of Series D-1 Preferred Stock to Common Stock	(1,999)
Net loss
Other comprehensive (loss) income
Balance	241,440,106	240,742,061	210,178,197	209,744,736	209,421,800	209,420,675	241,440,106	209,744,736
AOCI Attributable to Parent [Member]
Balance	(34,381)	(33,260)	(34,097)	(30,802)	(33,035)	(24,008)	(34,097)	(24,008)
Common stock issued for services
Common stock issued upon exercise of warrants
Common stock
Warrants issued for services
Conversion of PRH Notes to Series D Preferred Stock
Conversion of PRH Notes to Series D-1 Preferred Stock
Conversion of Series B Preferred Stock to Common Stock
Conversion of Series D-1 Preferred Stock to Common Stock
Net loss
Other comprehensive (loss) income	(193)	(1,121)	837	(1,652)	2,233	(9,027)
Balance	(34,574)	(34,381)	(33,260)	(32,454)	(30,802)	(33,035)	(34,574)	(32,454)
Retained Earnings [Member]
Balance	(243,743,956)	(242,164,365)	(240,494,415)	(237,258,694)	(235,643,889)	(233,816,828)	(240,494,415)	(233,816,828)
Common stock issued for services
Common stock issued upon exercise of warrants
Common stock
Warrants issued for services
Conversion of PRH Notes to Series D Preferred Stock
Conversion of PRH Notes to Series D-1 Preferred Stock
Conversion of Series B Preferred Stock to Common Stock
Conversion of Series D-1 Preferred Stock to Common Stock
Net loss	(1,051,259)	(1,579,591)	(1,669,950)	(1,564,444)	(1,614,805)	(1,827,061)
Other comprehensive (loss) income
Balance	(244,795,215)	(243,743,956)	(242,164,365)	(238,823,138)	(237,258,694)	(235,643,889)	(244,795,215)	(238,823,138)
Series B Preferred Stock [Member] | Preferred Stock [Member]
Balance
Beginning balance, shares	100	100	100	100	100	100	100	100
Common stock issued for services
Common stock issued upon exercise of warrants
Common stock
Warrants issued for services
Conversion of PRH Notes to Series D Preferred Stock
Conversion of PRH Notes to Series D-1 Preferred Stock
Conversion of Series B Preferred Stock to Common Stock
Conversion of Series B Preferred Stock to Common Stock, shares	(100)
Conversion of Series D-1 Preferred Stock to Common Stock
Net loss
Other comprehensive (loss) income
Balance
Ending balance, shares		100	100	100	100	100		100
Series D Preferred Stock [Member] | Preferred Stock [Member]
Balance	$ 12,373
Beginning balance, shares	12,373,247
Common stock issued for services
Common stock issued upon exercise of warrants
Common stock
Warrants issued for services
Conversion of PRH Notes to Series D Preferred Stock		$ 12,373
Conversion of PRH notes to series D preferred stock, Shares		12,373,247
Conversion of PRH Notes to Series D-1 Preferred Stock
Conversion of Series B Preferred Stock to Common Stock
Conversion of Series D-1 Preferred Stock to Common Stock
Net loss
Other comprehensive (loss) income
Balance	$ 12,373	$ 12,373					$ 12,373
Ending balance, shares	12,373,247	12,373,247					12,373,247
Series D 1 Preferred Stock [Member] | Preferred Stock [Member]
Balance	$ 9,441
Beginning balance, shares	9,440,594
Common stock issued for services
Common stock issued upon exercise of warrants
Common stock
Warrants issued for services
Conversion of PRH Notes to Series D Preferred Stock
Conversion of PRH Notes to Series D-1 Preferred Stock		$ 9,441
Conversion of PRH notes to series D-1 preferred stock, Shares		9,440,594
Conversion of Series B Preferred Stock to Common Stock
Conversion of Series D-1 Preferred Stock to Common Stock	$ (222)
Conversion of Series D-1 Preferred Stock to Common Stock	(222,145)
Net loss
Other comprehensive (loss) income
Balance	$ 9,219	$ 9,441					$ 9,219
Ending balance, shares	9,218,449	9,440,594					9,218,449
Series D-1 Convertible Preferred Stock [Member] | Preferred Stock [Member]
Beginning balance, shares

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash Flows From Operating Activities:
Net loss	$ (4,300,800)	$ (5,006,310)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	23,688	4,828
Non-cash lease expense	62,085	55,190
Depreciation	9,648	10,467
Amortization of patents		228,107
Forgiveness of PPP Loan	(62,500)
Changes in operating assets and liabilities
Short term receivables	2,448	47,250
Prepaid expenses	145,639	185,329
Accounts payable - trade	302,978	(61,026)
Other accrued expenses	306,116	187,705
Operating lease liability	(66,246)	(58,437)
Accrued interest expense	941,663	1,278,665
Net Cash Used In Operating Activities	(2,635,281)	(3,128,232)
Cash Flows From Financing Activities:
Proceeds from issuance of convertible notes payable	1,700,000	3,000,000
Proceeds from issuance of convertible notes payable - related parties	200,000	100,000
Deposit for purchase of Series D-1 Preferred Stock	150,000
Repayment of short-term note payable	(219,172)
Proceeds from note payable		62,500
Proceeds from exercise of warrants	962,223	368,040
Net Cash Provided By Financing Activities	2,793,051	3,530,540
Effect of Exchange Rate Changes on Cash	(918)	(6,492)
Net Increase In Cash and Cash Equivalents	156,852	395,816
Cash and Cash Equivalents, Beginning of Period	97,231	590,706
Cash and Cash Equivalents, End of Period	254,083	986,522
Cash paid during the period for:
Interest
Income taxes
Non-cash investing and financing activities:
Purchase of insurance policies financed by short-term note payable	(282,667)
Conversion of non-amended 2017 Notes to Series D Preferred Stock	3,541,222
Conversion of amended 2017 Notes and 2020 Notes to Series D-1 Preferred Stock	27,031,858
Conversion of Series D-1 Preferred Stock to Common Stock	$ 222

Business Organization, Nature o

Business Organization, Nature of Operations and Basis of Presentation	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Organization, Nature of Operations and Basis of Presentation	1. Business Organization, Nature of Operations and Basis of Presentation Provectus Biopharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, “Provectus” or the “Company”), is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases, with the aim of maximizing the curative impact of these medicines and achieving immunity from treated disease. These investigational drugs are based on a wholly owned class of small molecules called halogenated xanthenes (“HXs”). Our lead HX molecule is named rose bengal disodium (“RBD”). ● Oncology: ® Oral formulations of cGMP RBD are also undergoing preclinical study as prophylactic and therapeutic treatments for high-risk and refractory adult solid tumor cancers, such as head and neck, breast, colorectal, and testicular cancers. In vivo ● Pediatric Oncology: ● Hematology: In vivo ● Virology: In silico In vitro ● Microbiology: ● Ophthalmology: ● Dermatology: ® ● Animal Health: To date, the Company has not generated any revenues or profits from planned principal operations. The Company’s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company’s prescription drug candidates. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be reviewed in conjunction with the Company’s audited consolidated financial statements included in the Company’s Form 10-K for the year ended December 31, 2020 filed with the SEC on March 2, 2021. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. SARS-CoV-2 was reportedly first identified in late-2019 and subsequently declared a global pandemic by the World Health Organization on March 11, 2020. As a result of the SARS-CoV-2 pandemic, many companies have experienced disruptions of their operations and the markets they serve. The Company has taken several temporary precautionary measures intended to help ensure the well-being of its employees and contractors and to minimize business disruption. The Company considered the impact of SARS-CoV-2 pandemic on its business and operational assumptions and estimates, and determined there were no material adverse impacts on the Company’s results of operations and financial position at September 30, 2021. The full extent of the SARS-CoV-2 pandemic impacts on the Company’s operations and financial condition is uncertain. The Company has experienced slower than normal enrollment and treatment of patients, and a prolonged SARS-CoV-2 pandemic could have a material adverse impact on the Company’s business and financial results, including the timing and ability of the Company to raise capital, initiate and/or complete current and/or future preclinical studies and/or clinical trials; disrupt the Company’s regulatory activities; and/or have other adverse effects on the Company’s clinical development.

Liquidity and Going Concern

Liquidity and Going Concern	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Going Concern	2. Liquidity and Going Concern The Company’s cash and cash equivalents were $ 254,083 The Company plans to access capital resources through possible public or private equity offerings, including the 2021 financing (as defined in Note 4), exchange offers, debt financings, corporate collaborations, or other means. In addition, the Company continues to explore opportunities to strategically monetize its lead drug candidates, PV-10 and PH-10, through potential co-development and licensing transactions, although there can be no assurance that the Company will be successful with such plans. The Company has historically been able to raise capital through equity offerings, although no assurance can be provided that it will continue to be successful in the future. If the Company is unable to raise sufficient capital, it will not be able to pay its obligations as they become due. The primary business objective of management is to build the Company into a commercial-stage biotechnology company; however, the Company cannot assure that it will be successful in co-developing, licensing, and/or commercializing PV-10, PH-10, and/or any other halogenated xanthene-based drug candidate developed by the Company or entering into any financial transaction. Moreover, even if the Company is successful in improving its current cash flow position, the Company nonetheless plans to seek additional funds to meet its long-term requirements in 2021 and beyond. The Company anticipates that these funds will otherwise come from the proceeds of private placement transactions, the exercise of existing warrants and outstanding stock options, or public offerings of debt or equity securities. While the Company believes that it has a reasonable basis for its expectation that it will be able to raise additional funds, the Company cannot provide assurance that it will be able to complete additional financing in a timely manner. In addition, any such financing may result in significant dilution to stockholders.

Critical Accounting Policies

Critical Accounting Policies	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Critical Accounting Policies	3. Critical Accounting Policies Since the date the Company’s December 31, 2020 consolidated financial statements were issued in its 2020 Annual Report, there have been no material changes to the Company’s significant accounting policies, except as disclosed below. Recently Adopted Accounting Standards In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2019-12, Simplifying the Accounting for Income Taxes. Income Taxes Convertible Instruments The Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted for in accordance with ASC Topic 815: Derivatives and Hedging If the instrument is determined to not be a derivative liability, the Company then evaluates for the existence of a beneficial conversion feature by comparing the commitment date fair value to the effective conversion price of the instrument. Preferred Stock The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders’ deficiency. Basic and Diluted Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares September 30, September 30, 2021 2020 Warrants 512,500 89,699,866 Options 3,625,000 2,275,000 Convertible preferred stock 104,557,737 65,666 Total potentially dilutive shares 108,695,237 92,040,532

Convertible Notes Payable

Convertible Notes Payable	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Convertible Notes Payable	4. Convertible Notes Payable 2017 Financing On March 23, 2017, the Company entered into a 2017 Term Sheet with the PRH Group that set forth the terms on which the PRH Group would use their best efforts to arrange for a financing of a minimum of $ 10,000,000 20,000,000 20,067,000 6,770,000 2020 Financing On December 31, 2019, the Board approved a Definitive Financing Term Sheet (the “2020 Term Sheet”), which sets forth the terms under which the Company would use its best efforts to arrange for financing of a maximum of $ 20,000,000 (the “2020 Financing”). The 2020 Financing was in the form of secured convertible loans from investors that were evidenced by secured convertible promissory notes (the “2020 Notes”). The 2020 Term Sheet was similar to the 2017 Term Sheet. Subject to the terms and conditions of the 2020 Term Sheet, the Company used its best efforts to arrange for the 2020 Financing, which amounts were obtained in several tranches. Cumulatively through September 30, 2021 and December 31, 2020, the Company had received proceeds of $ 5,025,000 and $ 3,325,000 , respectively, in connection with the 2020 Financing, of which $ 100,000 was received from related parties. Firm Commitment Previously, the Company had not designated the Series D Preferred Stock into which the 2017 Notes and the 2020 Notes (collectively the “Notes”) were convertible into. As a result, the Company did not analyze the Notes for a potential beneficial conversion feature as the definition of a firm commitment had not been met since the Notes were not yet convertible. On June 17, 2021, the required Certificates of Designation were filed with the Delaware Secretary of State. Accordingly, a firm commitment was achieved. The Company analysed the Notes for a beneficial conversion feature and determined that there was none because the Notes have an effective conversion price of $ 0.2862 per share of underlying common stock, which exceeds the $ 0.07 per share commitment date closing market price of the common stock. The Series D and D-1 Convertible Preferred Stock The 2017 Notes originally provided that they were convertible into a new class of the Company’s preferred stock, $ 0.001 0.2862 0.001 In order to ensure that the Company had sufficient authorized shares of Preferred Stock into which the 2017 Notes would convert, yet keep the economic terms of the 2017 Notes substantially equivalent, the Company entered into amendments (the “Amendments”) to the 2017 Notes (as amended, the “Amended 2017 Notes”) with a large majority of the holders of 2017 Notes to increase the conversion price by 10 times from $ 0.2862 2.862 In order to (i) address the fact that a small minority of the holders of 2017 Notes did not execute the Amendments and (ii) ensure economic fairness for all of the holders of the 2017 Notes and 2020 Notes, the Company designated two separate classes of Preferred Stock into which the 2017 Notes and 2020 Notes would convert: (i) the Company’s Series D Convertible Preferred Stock, par value $ 0.001 0.001 On June 20, 2021, the outstanding non-amended 2017 Notes converted into 12,373,247 0.2862 9,440,594 2.862 As a result of the conversion of the 2017 Notes and 2020 Notes into convertible preferred stock, all the security interests of these notes in the Company’s intellectual property were released. The rights, preferences and privileges of the Series D Convertible Preferred Stock are set forth in a Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock (the “Series D Certificate of Designation”). The rights, preferences and privileges of the Series D-1 Convertible Preferred Stock are set forth in a Certificate of Designation of Preferences, Rights and Limitations of Series D-1 Convertible Preferred Stock (the “Series D-1 Certificate of Designation”). The Board of Directors of the Company approved each of the Series D Certificate of Designation and Series D-1 Certificate of Designation on June 16, 2021, and each of the Series D Certificate of Designation and Series D-1 Certificate of Designation were filed with the Delaware Secretary of State on June 17, 2021. The Series D Certificate of Designation and Series D-1 Certificate of Designation are the same, other than certain key differences to account solely for the different conversion ratios for the holders of 2017 Notes who did not execute Amendments compared to the holders of Amended 2017 Notes and the holders of 2020 Notes. Number of Shares The Series D Certificate of Designation established and designated 12,374,000 9,441,000 Rank The Series D Convertible Preferred Stock and the Series D-1 Convertible Preferred Stock rank pari passu pari passu Dividends The Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock do not have any dividend preference but are entitled to receive, on a pari passu Liquidation Preference Upon the occurrence of the liquidation, winding-up or dissolution of the Company or certain mergers, corporate reorganizations or sales of the Company’s assets (each, a “Company Event”), holders of Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock will be entitled to receive a liquidation preference before any distributions are made to holders of any other class or series of the Company’s capital stock junior to the Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock. If a Company Event occurs within two years of June 20, 2021 (the “Date of Issuance”), the holders of Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock will receive for each share of Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock, respectively, an amount in cash equal to the Original Issue Price (as defined in the Series D Certificate of Designation and Series D-1 Certificate of Designation, respectively) multiplied by four. If a Company Event occurs from and after the second anniversary of the Date of Issuance, the holders of Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock will receive for each share of Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock, respectively, an amount in cash equal to the Original Issue Price multiplied by six. The Original Issue Price for the Series D Convertible Preferred Stock is $ 0.2862 2.862 Voting Rights Holders of shares of Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock will vote together with the holders of Common Stock as a single class. Each share of Series D Convertible Preferred Stock carries the right to one vote per share. Each share of Series D-1 Convertible Preferred Stock carries the right to 10 votes per share The Company is not permitted to amend, alter or repeal its Certificate of Incorporation or Bylaws in a manner adverse to the relative rights, preferences, qualifications, limitations or restrictions of the Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock without the affirmative vote of a majority of the votes entitled to be cast by holders of outstanding shares of Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock, voting together as a single class with each share of Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock having a number of votes equal to the number of shares of Common Stock then issuable upon conversion of such share of Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock. Series D and Series D-1 Conversion The Series D Convertible Preferred Stock is convertible at the option of the holders thereof into shares of Common Stock based on a one-for-one conversion ratio. The Series D-1 Convertible Preferred Stock is convertible at the option of the holders thereof into shares of Common Stock based on a one-for-10 conversion ratio. The conversion ratio of the Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock is subject to adjustment for stock splits and combinations, recapitalizations, reclassifications, reorganizations, mergers, and consolidations. The Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock will automatically convert into shares of Common Stock upon the fifth anniversary of the Date of Issuance. During the three months ended September 30, 2021, a holder of 222,145 2,221,450 2021 Financing On August 13, 2021, the Board approved a Financing Term Sheet (the “2021 Term Sheet”), which sets forth the terms under which the Company will use its best efforts to arrange for financing of a maximum of $ 5,000,000 As of September 30, 2021, the Company had received a 2021 Loan, as defined below, of $ 200,000 Pursuant to the 2021 Term Sheet, the 2021 Notes (defined below) will be paid back, convert into shares of the Company’s Series D-1 Preferred Stock, or convert into Company equity securities and/or debt instruments of certain future financings on or before twelve months after the issue date of a 2021 Note, subject to certain exceptions. The 2021 Financing will be in the form of an unsecured convertible loans (the “2021 Loan”) from the investors (the “2021 Loan Investors”) and evidenced by convertible promissory notes (individually, a “2021 Note” and collectively, the “2021 Notes”). In addition to customary provisions, the 2021 Notes will contain the following provisions: (i) The 2021 Loan will bear interest at the rate of eight percent ( 8 (ii) In the event there is a change of control of the Board, the term of the 2021 Notes will be accelerated and all amounts due under the 2021 Notes may be immediately due and payable at the 2021 Loan Investors’ option; (iii) The outstanding principal amount and interest payment under the 2021 Loan may be paid back at maturity at the 2021 Loan Investors’ option; (iv) The outstanding principal amount and interest payable under the 2021 Loan may be convertible at the 2021 Loan Investors’ option into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $ 2.8620 . The Series D-1 Convertible Preferred Stock is convertible into ten ( 10 ) shares of common stock; and (v) In the event the Company conducts a qualified equity or debt financing and the Company receives gross proceeds in the aggregate amount of $ 20 The embedded conversion options associated with the 2021 Note do not require bifurcation and treatment as a derivative liability and they do not represent a beneficial conversion feature because the effective conversion price is not at a discount to the commitment date market price.

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2021
Notes Payable
Notes Payable	5. Notes Payable On April 20, 2020, the Company received a $ 62,500 The PPP provides for loans to qualifying businesses for amounts of up to 2.5 times certain of the borrower’s average monthly payroll expenses. The Company obtained short-term financing from AFCO Insurance Premium Finance for our commercial insurance policies. As of September 30, 2021 and December 31, 2020, the balance of the note payable was $ 68,392 212,790

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2021
Related Party Transactions [Abstract]
Related Party Transactions	6. Related Party Transactions During the three months ended September 30, 2021 and September 30, 2020, the Company paid Mr. Bruce Horowitz (Capital Strategists) consulting fees of $ 21,200 127,200 During the nine months ended September 30, 2021 and September 30, 2020, the Company paid Mr. Bruce Horowitz (Capital Strategists) consulting fees of $ 148,400 190,800 Accrued director fees for Mr. Horowitz as of September 30, 2021 and December 31, 2020 were $ 56,250 75,000 See Note 4 for details of other related party transactions. Director fees during the three months ended September 30, 2021 and September 30, 2020 were $ 96,250 96,250 Director fees during the nine months ended September 30, 2021 and September 30, 2020 were $ 288,750 288,750 Accrued directors’ fees as of September 30, 2021 and December 31, 2020 were $ 1,464,339 1,175,589

Short-term Receivables

Short-term Receivables	9 Months Ended
	Sep. 30, 2021
Receivables [Abstract]
Short-term Receivables	7. Short-term Receivables The following table summarizes the receivables at September 30, 2021 and December 31, 2020: Summary of Short-term Receivables September 30, 2021 Tax Credit Legal Fees Settlement Total Provectus Australia Tax Credit $ 1,354 $ - $ - $ 1,354 Gross receivable - 455,500 1,649,043 2,104,543 Reserve for uncollectibility - (455,500 ) (1,649,043 ) (2,104,543 ) Net receivable $ 1,354 $ - $ - $ 1,354 December 31, 2020 Tax Credit Legal Fees Settlement Total Provectus Australia Tax Credit $ 3,930 $ - $ - $ 3,930 Gross receivable - 455,500 1,649,043 2,104,543 Reserve for uncollectibility - (455,500 ) (1,649,043 ) (2,104,543 ) Net receivable $ 3,930 $ - $ - $ 3,930

Stockholders_ Deficiency

Stockholders’ Deficiency	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Stockholders’ Deficiency	8. Stockholders’ Deficiency Common Stock During the nine months ended September 30, 2021, the Company issued an aggregate of 300,000 23,200 During the nine months ended September 30, 2021, the Company issued 2,221,450 shares of common stock upon the voluntary conversion of Series D-1 Convertible Preferred Stock. During the nine months ended September 30, 2021, the Company issued 65,666 shares of common stock upon the automatic conversion of Series B Convertible Preferred Stock. Preferred Stock On June 20, 2021, the Company issued 12,373,247 9,440,594 During the nine months ended September 30, 2021, the Company received total investments of $ 150,000 52,411 Options During the nine months ended September 30, 2021, a total of 1,175,000 The following table summarizes option activity during the nine months ended September 30, 2021: Schedule of Stock Option Activity Weighted Average Shares Exercise Price Outstanding and exercisable at January 1, 2021 4,800,000 $ 0.46 Granted - - Exercised - - Forfeited (1,175,000 ) 0.98 Outstanding and exercisable at September 30, 2021 3,625,000 $ 0.32 The following table summarizes information about options outstanding at September 30, 2021: Summary of Stock Options Outstanding Number Outstanding and Exercisable Weighted Average Intrinsic Value at September 30, Remaining Contractual at September 30, Exercise Price 2021 Life 2021 $ 0.12 2,425,000 4.10 $ - $ 0.29 100,000 4.10 $ - $ 0.67 200,000 1.90 $ - $ 0.75 550,000 4.20 $ - $ 0.84 150,000 0.70 $ - $ 0.88 150,000 2.80 $ - $ 0.93 50,000 0.60 $ - 3,625,000 3.77 $ - Warrants During the nine months ended September 30, 2021, the Company granted three-year immediately vested warrants to purchase an aggregate of 25,000 0.2862 488 During the nine months ended September 30, 2021, warrant holders exercised warrants to purchase an aggregate of 18,052,966 0.0533 962,223 68,723,698 August 2016 The following table summarizes warrant activity during the nine months ended September 30, 2021: Summary of Warrant Activity Weighted Average Shares Exercise Price Outstanding and exercisable at January 1, 2021 87,264,164 $ 0.02 Granted 25,000 0.29 Exercised (18,052,966 ) 0.05 Forfeited (68,723,698 ) 0.05 Outstanding and exercisable at September 30, 2021 512,500 $ 0.92 The following table summarizes information about warrants outstanding at September 30, 2021: Summary of Warrants Outstanding Number Outstanding and Exercisable at September 30, Weighted Average Remaining Contractual Intrinsic Value at September 30, Exercise Price 2021 Life 2021 $ 0.29 125,000 1.75 $ - $ 1.00 18,000 2.64 $ - $ 1.12 366,000 2.64 $ - $ 2.00 3,500 2.64 $ - 512,500 2.42 $ - Holders of the outstanding warrants are not entitled to vote and the exercise prices of such warrants are subject to customary anti-dilution provisions.

Leases

Leases	9 Months Ended
	Sep. 30, 2021
Leases
Leases	9. Leases The Company currently leases 4,500 five years ending on June 30, 2022 . Payments are approximately $ 7,900 per month. On August 13, 2021, the Company negotiated a reduced rent from July 1, 2021 through December 31, 2021 in the amount of $ 6,100 per month. Total operating lease expense for the three months ended September 30, 2021 was $ 15,887 10,591 5,296 24,446 16,297 8,149 Total operating lease expense for the nine months ended September 30, 2021 was $ 63,693 42,462 21,231 68,080 45,387 22,693 A summary of the Company’s right-of-use assets and liabilities is as follows: Schedule of Right-of-Use Assets and Liabilities For The Nine Months Ended September 30, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases $ 64,231 $ 67,774 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ - $ - Weighted Average Remaining Lease Term Operating leases 9 months 1 year 9 months Weighted Average Discount Rate Operating leases 8.0 % 8.0 % Future minimum payments under the Company’s non-cancellable lease obligations as of September 30, 2021 were as follows: Schedule of Future Minimum Payment for Lease Years Amount 2021 $ 18,447 2022 46,687 Total future minimum lease payments 65,134 Less: amount representing imputed interest (2,214 ) Total $ 62,920

Commitments, Contingencies and

Commitments, Contingencies and Litigation	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments, Contingencies and Litigation	10. Commitments, Contingencies and Litigation The Company may, from time to time, be involved in litigation arising in the ordinary course of business or which may be expected to be covered by insurance. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	11. Subsequent Events The Company has evaluated events that have occurred after the balance sheet and through the date the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed below. On October 25, 2021, the Company’s grant award of $ 2,500,000 from the State of Tennessee for the study of animal cancers and dermatological disorders for the period October 15, 2021 to June 30, 2022 was funded.

Critical Accounting Policies (P

Critical Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2019-12, Simplifying the Accounting for Income Taxes. Income Taxes
Convertible Instruments	Convertible Instruments The Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted for in accordance with ASC Topic 815: Derivatives and Hedging If the instrument is determined to not be a derivative liability, the Company then evaluates for the existence of a beneficial conversion feature by comparing the commitment date fair value to the effective conversion price of the instrument.
Preferred Stock	Preferred Stock The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders’ deficiency.
Basic and Diluted Loss Per Common Share	Basic and Diluted Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares September 30, September 30, 2021 2020 Warrants 512,500 89,699,866 Options 3,625,000 2,275,000 Convertible preferred stock 104,557,737 65,666 Total potentially dilutive shares 108,695,237 92,040,532

Critical Accounting Policies (T

Critical Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares	Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares September 30, September 30, 2021 2020 Warrants 512,500 89,699,866 Options 3,625,000 2,275,000 Convertible preferred stock 104,557,737 65,666 Total potentially dilutive shares 108,695,237 92,040,532

Short-term Receivables (Tables)

Short-term Receivables (Tables)	9 Months Ended
	Sep. 30, 2021
Receivables [Abstract]
Summary of Short-term Receivables	The following table summarizes the receivables at September 30, 2021 and December 31, 2020: Summary of Short-term Receivables September 30, 2021 Tax Credit Legal Fees Settlement Total Provectus Australia Tax Credit $ 1,354 $ - $ - $ 1,354 Gross receivable - 455,500 1,649,043 2,104,543 Reserve for uncollectibility - (455,500 ) (1,649,043 ) (2,104,543 ) Net receivable $ 1,354 $ - $ - $ 1,354 December 31, 2020 Tax Credit Legal Fees Settlement Total Provectus Australia Tax Credit $ 3,930 $ - $ - $ 3,930 Gross receivable - 455,500 1,649,043 2,104,543 Reserve for uncollectibility - (455,500 ) (1,649,043 ) (2,104,543 ) Net receivable $ 3,930 $ - $ - $ 3,930

Stockholders_ Deficiency (Table

Stockholders’ Deficiency (Tables)	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Schedule of Stock Option Activity	The following table summarizes option activity during the nine months ended September 30, 2021: Schedule of Stock Option Activity Weighted Average Shares Exercise Price Outstanding and exercisable at January 1, 2021 4,800,000 $ 0.46 Granted - - Exercised - - Forfeited (1,175,000 ) 0.98 Outstanding and exercisable at September 30, 2021 3,625,000 $ 0.32
Summary of Stock Options Outstanding	The following table summarizes information about options outstanding at September 30, 2021: Summary of Stock Options Outstanding Number Outstanding and Exercisable Weighted Average Intrinsic Value at September 30, Remaining Contractual at September 30, Exercise Price 2021 Life 2021 $ 0.12 2,425,000 4.10 $ - $ 0.29 100,000 4.10 $ - $ 0.67 200,000 1.90 $ - $ 0.75 550,000 4.20 $ - $ 0.84 150,000 0.70 $ - $ 0.88 150,000 2.80 $ - $ 0.93 50,000 0.60 $ - 3,625,000 3.77 $ -
Summary of Warrant Activity	The following table summarizes warrant activity during the nine months ended September 30, 2021: Summary of Warrant Activity Weighted Average Shares Exercise Price Outstanding and exercisable at January 1, 2021 87,264,164 $ 0.02 Granted 25,000 0.29 Exercised (18,052,966 ) 0.05 Forfeited (68,723,698 ) 0.05 Outstanding and exercisable at September 30, 2021 512,500 $ 0.92
Summary of Warrants Outstanding	The following table summarizes information about warrants outstanding at September 30, 2021: Summary of Warrants Outstanding Number Outstanding and Exercisable at September 30, Weighted Average Remaining Contractual Intrinsic Value at September 30, Exercise Price 2021 Life 2021 $ 0.29 125,000 1.75 $ - $ 1.00 18,000 2.64 $ - $ 1.12 366,000 2.64 $ - $ 2.00 3,500 2.64 $ - 512,500 2.42 $ -

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2021
Leases
Schedule of Right-of-Use Assets and Liabilities	A summary of the Company’s right-of-use assets and liabilities is as follows: Schedule of Right-of-Use Assets and Liabilities For The Nine Months Ended September 30, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases $ 64,231 $ 67,774 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ - $ - Weighted Average Remaining Lease Term Operating leases 9 months 1 year 9 months Weighted Average Discount Rate Operating leases 8.0 % 8.0 %
Schedule of Future Minimum Payment for Lease	Future minimum payments under the Company’s non-cancellable lease obligations as of September 30, 2021 were as follows: Schedule of Future Minimum Payment for Lease Years Amount 2021 $ 18,447 2022 46,687 Total future minimum lease payments 65,134 Less: amount representing imputed interest (2,214 ) Total $ 62,920

Liquidity and Going Concern (De

Liquidity and Going Concern (Details Narrative) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 254,083	$ 97,231

Schedule of Securities Excluded

Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares (Details) - shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	108,695,237	92,040,532
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	512,500	89,699,866
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	3,625,000	2,275,000
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	104,557,737	65,666

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	Jun. 20, 2021	Sep. 30, 2021	Sep. 30, 2021	Dec. 31, 2020	Aug. 13, 2021	Dec. 31, 2019	Mar. 23, 2017
Debt Instrument [Line Items]
Preferred Stock, Par or Stated Value Per Share		$ 0.001	$ 0.001	$ 0.001
Common Stock, Par or Stated Value Per Share				$ 0.001
Preferred Stock, Shares Authorized		25,000,000	25,000,000	25,000,000
Preferred Stock, Voting Rights			Holders of shares of Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock will vote together with the holders of Common Stock as a single class. Each share of Series D Convertible Preferred Stock carries the right to one vote per share. Each share of Series D-1 Convertible Preferred Stock carries the right to 10 votes per share
Debt instrument, interest rate, stated percentage		8.00%	8.00%
Investors [Member]
Debt Instrument [Line Items]
Proceeds from loans			$ 200,000
Series D Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Preferred Stock, Shares Authorized		12,374,000	12,374,000	12,374,000
Series D-1 Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Preferred Stock, Shares Authorized		9,441,000	9,441,000	9,441,000
Series D-1 Convertible Preferred Stock [Member] | Investors [Member]
Debt Instrument [Line Items]
Number of shares issued upon conversion		10
Sale of Stock, Price Per Share		$ 2.8620	$ 2.8620
Proceeds from debt financing		$ 20,000,000
Series D-1 Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Number of shares converted		222,145
Number of shares issued upon conversion			2,221,450
Common Stock [Member]
Debt Instrument [Line Items]
Number of shares issued upon conversion		2,221,450
Firm Commitment [Member]
Debt Instrument [Line Items]
Share Price		$ 0.07	$ 0.07
Minimum [Member] | Firm Commitment [Member]
Debt Instrument [Line Items]
Effective conversion price		0.2862	$ 0.2862
2017 Financing [Member]
Debt Instrument [Line Items]
Proceeds from loans			$ 20,067,000
Proceeds from Related Party Debt			$ 6,770,000
2017 Financing [Member] | First And Final Tranche [Member]
Debt Instrument [Line Items]
Financing arrangement amount					$ 5,000,000
2017 Financing [Member] | Series D And D1 Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Preferred Stock, Par or Stated Value Per Share		0.001	$ 0.001
Preferred Stock, Convertible, Conversion Price		0.2862	0.2862
Common Stock, Par or Stated Value Per Share		0.001	0.001
2017 Financing [Member] | Series D Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Preferred Stock, Par or Stated Value Per Share		0.001	0.001
2017 Financing [Member] | Minimum [Member]
Debt Instrument [Line Items]
Financing arrangement amount							$ 10,000,000
2017 Financing [Member] | Minimum [Member] | Series D And D1 Convertible Preferred Stock [Member] | Final Tranche [Member]
Debt Instrument [Line Items]
Preferred Stock, Convertible, Conversion Price		0.2862	0.2862
2017 Financing [Member] | Maximum [Member]
Debt Instrument [Line Items]
Financing arrangement amount							$ 20,000,000
2017 Financing [Member] | Maximum [Member] | Series D And D1 Convertible Preferred Stock [Member] | Final Tranche [Member]
Debt Instrument [Line Items]
Preferred Stock, Convertible, Conversion Price		$ 2.862	$ 2.862
2020 Financing [Member]
Debt Instrument [Line Items]
Proceeds from loans			$ 5,025,000	$ 3,325,000
Proceeds from Related Party Debt			$ 100,000
2020 Financing [Member] | Maximum [Member]
Debt Instrument [Line Items]
Financing arrangement amount						$ 20,000,000
Non Amended 2017 Financing [Mmber] | Series D Convertible Preferred Stock [Member] | 2020 Notes [Member]
Debt Instrument [Line Items]
Effective conversion price	$ 0.2862
Debt conversion, shares issued	12,373,247
Amended 2017 [Member] | Series D-1 Convertible Preferred Stock [Member] | 2020 Notes [Member]
Debt Instrument [Line Items]
Effective conversion price	$ 2.862
Debt conversion, shares issued	9,440,594

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	Apr. 20, 2020	Sep. 30, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Notes Payable		$ 68,392	$ 212,790
Paycheck Protection Program [Member] | CARES Act [Member]
Short-term Debt [Line Items]
Proceeds from loan	$ 62,500
Debt instrument description	The PPP provides for loans to qualifying businesses for amounts of up to 2.5 times certain of the borrower’s average monthly payroll expenses.

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Accrued Professional Fees	$ 1,464,339		$ 1,464,339		$ 1,175,589
Director fees	96,250	$ 96,250	288,750	$ 288,750
Mr Bruce Horowitz [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Professional Fees	21,200	$ 127,200	148,400	$ 190,800
Accrued Professional Fees	$ 56,250		$ 56,250		$ 75,000

Summary of Short-term Receivabl

Summary of Short-term Receivables (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Accounts, Notes, Loans and Financing Receivable [Line Items]
Tax Credit	$ 1,354	$ 3,930
Gross receivable	2,104,543	2,104,543
Reserve for uncollectibility	(2,104,543)	(2,104,543)
Net receivable	1,354	3,930
Legal Fees [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Tax Credit
Gross receivable	455,500	455,500
Reserve for uncollectibility	(455,500)	(455,500)
Net receivable
Settlement [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Tax Credit
Gross receivable	1,649,043	1,649,043
Reserve for uncollectibility	(1,649,043)	(1,649,043)
Net receivable
Australian Taxation Office [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Tax Credit	1,354	3,930
Gross receivable
Reserve for uncollectibility
Net receivable	$ 1,354	$ 3,930

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details)	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Equity [Abstract]
Number of Options Outstanding and exercisable, beginning balance | shares	4,800,000
Weighted Average Exercise Price Outstanding and exercisable, beginning balance | $ / shares	$ 0.46
Number of Options, Granted | shares
Weighted Average Exercise Price, Granted | $ / shares
Number of Options, Exercised | shares
Weighted Average Exercise Price, Exercised | $ / shares
Number of Options, Forfeited | shares	(1,175,000)
Weighted Average Exercise Price, Forfeited | $ / shares	$ 0.98
Number of Options Outstanding and exercisable, ending balance | shares	3,625,000
Weighted Average Exercise Price Outstanding and exercisable, ending balance | $ / shares	$ 0.32

Summary of Stock Options Outsta

Summary of Stock Options Outstanding (Details)	9 Months Ended
	Sep. 30, 2021USD ($)$ / sharesshares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding | shares	3,625,000
Weighted Average Remaining Contractual Life	3 years 9 months 7 days
Intrinsic value | $
Range one [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 0.12
Number Outstanding | shares	2,425,000
Weighted Average Remaining Contractual Life	4 years 1 month 6 days
Intrinsic value | $
Range Two [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 0.29
Number Outstanding | shares	100,000
Weighted Average Remaining Contractual Life	4 years 1 month 6 days
Intrinsic value | $
Range Three [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 0.67
Number Outstanding | shares	200,000
Weighted Average Remaining Contractual Life	1 year 10 months 24 days
Intrinsic value | $
Range Four [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 0.75
Number Outstanding | shares	550,000
Weighted Average Remaining Contractual Life	4 years 2 months 12 days
Intrinsic value | $
Range Five [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 0.84
Number Outstanding | shares	150,000
Weighted Average Remaining Contractual Life	8 months 12 days
Intrinsic value | $
Range Six [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 0.88
Number Outstanding | shares	150,000
Weighted Average Remaining Contractual Life	2 years 9 months 18 days
Intrinsic value | $
Range Seven [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 0.93
Number Outstanding | shares	50,000
Weighted Average Remaining Contractual Life	7 months 6 days
Intrinsic value | $

Summary of Warrant Activity (De

Summary of Warrant Activity (Details)	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Equity [Abstract]
Warrants Outstanding and exercisable, beginning balance | shares	87,264,164
Weighted Average Exercise Price | $ / shares	$ 0.02
Warrants, Granted | shares	25,000
Weighted Average Exercise Price, Granted | $ / shares	$ 0.29
Warrants, Exercised | shares	(18,052,966)
Weighted Average Exercise Price, Exercised | $ / shares	$ 0.05
Warrants, Forfeited | shares	(68,723,698)
Weighted Average Exercise Price, Forfeited | $ / shares	$ 0.05
Warrants Outstanding and exercisable, ending balance | shares	512,500
Weighted Average Exercise Price | $ / shares	$ 0.92

Summary of Warrants Outstanding

Summary of Warrants Outstanding (Details)	9 Months Ended
	Sep. 30, 2021USD ($)$ / sharesshares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted Average Exercise price | $ / shares
Intrinsic value
Range one [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Intrinsic value
Range Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Intrinsic value
Range Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Intrinsic value
Range Four [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Intrinsic value
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number Outstanding and Exercisable | shares	512,500
Weighted Average Remaining Contractual Life	2 years 5 months 1 day
Intrinsic value
Warrant [Member] | Range one [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted Average Exercise price | $ / shares	$ 0.29
Number Outstanding and Exercisable | shares	125,000
Weighted Average Remaining Contractual Life	1 year 9 months
Intrinsic value
Warrant [Member] | Range Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted Average Exercise price | $ / shares	$ 1
Number Outstanding and Exercisable | shares	18,000
Weighted Average Remaining Contractual Life	2 years 7 months 20 days
Intrinsic value
Warrant [Member] | Range Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted Average Exercise price | $ / shares	$ 1.12
Number Outstanding and Exercisable | shares	366,000
Weighted Average Remaining Contractual Life	2 years 7 months 20 days
Intrinsic value
Warrant [Member] | Range Four [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted Average Exercise price | $ / shares	$ 2
Number Outstanding and Exercisable | shares	3,500
Weighted Average Remaining Contractual Life	2 years 7 months 20 days
Intrinsic value

Stockholders_ Deficiency (Detai

Stockholders’ Deficiency (Details Narrative) - USD ($)	Aug. 30, 2021	Jun. 20, 2021	Sep. 30, 2021	Sep. 30, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of options expired			1,175,000
Proceeds from issuance of warrants			$ 488
Proceeds from exercise of warrants			$ 962,223	$ 368,040
Number of warrants expired	68,723,698
Warrant expired description			August 2016
Series D-1 Convertible Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Conversion of Stock, Shares Issued			2,221,450
Series B Convertible Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Conversion of Stock, Shares Issued			65,666
Series D Convertible Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued		12,373,247
Series D-1 Convertible Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued		9,440,594
Series D-1 Convertible Preferred Stock [Member] | Non-related Party Investor [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued			52,411
Investment amount			$ 150,000
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross			300,000
Stock Issued During Period, Value, Restricted Stock Award, Gross			$ 23,200
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase shares			18,052,966
Exercise price per share			$ 0.0533
Proceeds from exercise of warrants			$ 962,223
Warrant [Member] | Advisory Board [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase shares			25,000
Exercise price per share			$ 0.2862

Schedule of Right-of-Use Assets

Schedule of Right-of-Use Assets and Liabilities (Details) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Leases
Operating Lease, Payments	$ 64,231	$ 67,774
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Operating lease, Weighted Average Remaining Lease Term	9 months	1 year 9 months
Operating Lease, Weighted Average Discount Rate, Percent	8.00%	8.00%

Schedule of Future Minimum Paym

Schedule of Future Minimum Payment for Lease (Details)	Sep. 30, 2021USD ($)
Leases
2021	$ 18,447
2022	46,687
Total future minimum lease payments	65,134
Less: amount representing imputed interest	(2,214)
Total	$ 62,920

Leases (Details Narrative)

Leases (Details Narrative)	3 Months Ended		6 Months Ended	9 Months Ended
	Sep. 30, 2021USD ($)ft²	Sep. 30, 2020USD ($)	Dec. 31, 2021USD ($)	Sep. 30, 2021USD ($)ft²	Sep. 30, 2020USD ($)
Operating Lease, Payments				$ 64,231	$ 67,774
Research and Development Expense [Member]
Operating Lease, Expense	$ 10,591	$ 16,297		42,462	45,387
General and Administrative Expense [Member]
Operating Lease, Expense	5,296	8,149		21,231	22,693
Property Subject to Operating Lease [Member]
Operating Lease, Expense	$ 15,887	$ 24,446		$ 63,693	$ 68,080
Subsequent Event [Member]
Payments for Rent			$ 6,100
Knoxville Tennessee [Member]
Area of Land | ft²	4,500			4,500
Lessee, Operating Lease, Term of Contract	5 years			5 years
Lease Expiration Date				Jun. 30, 2022
Operating Lease, Payments				$ 7,900

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	Oct. 25, 2021USD ($)
Subsequent Event [Member]
Subsequent Event [Line Items]
Award granted	$ 2,500,000